![](https://endpts.com/wp-content/uploads/2024/04/Marco-Quarta-Rubedo-Life-Sciences-tile.jpg)
Rubedo Life Sciences co-founder Julian Klein (foreground) with CEO Marco Quarta (courtesy Rubedo Life Sciences)
Rubedo pulls in $40M Series A to advance atopic dermatitis candidate targeting aging cells
Rubedo Life Sciences is furthering its plan to treat age-related diseases by targeting senescent cells with a $40 million Series A led by Khosla Ventures …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.